NuPathe (PATH) on the Radar on Sector Deal

January 23, 2013 7:23 AM EST Send to a Friend
Traders are eying NuPathe, Inc. (Nasdaq: PATH) after Allergan, Inc. (NYSE: AGN) agreed to acquire MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) for $25 per share, or a 60% premium.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Rumors, Trader Talk

Add Your Comment